Bortezomib dosing in relapsed multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 2, 2006, Pages 101-102

  Jagannath, Sundar ^a  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; METHYLPHENIDATE;

CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; EDITORIAL; FATIGUE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; SOLID TUMOR; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 33750150269     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.045     Document Type: Editorial

References (17)

1. Kane RC, Farrell AT, Sridhara R, et al. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006; 12:2955-2960.
2. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-172.
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
4. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498.
5. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial. Blood 2005; 106:715a.
6. Millennium Pharmaceuticals Inc. Velcade® (bortezomib) for Injection [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals, Inc; 2006.
7. Greco FA, Spigel DR, Barton JH, et al. Weekly bortezomib in the treatment of patients (pts) with previously treated multiple myeloma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2006; 24(18 suppl):433s (Abstract #7547).
8. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2108-2121.
9. Gertz MA, Garton JP, Greipp PR, et al. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 1995; 9:2115-2118.
10. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076.
11. Harousseau J, Attal M, Coiteux V, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. J Clin Oncol 2005; 23(16 suppl):598s (Abstract #6653).
12. Jagannath S, Durie B, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma. Blood 2005; 106:231a (Abstract #783).
13. Kropff MH, Bisping G, Winning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005; 29:587-590.
14. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91:929-934.
15. Lonial S, Richardson P, Sonneveld P, et al. Hematologic profiles in the phase 3 APEX trial. Blood 2005; 106:970a.
16. Lonial S, Weller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106:3777-3784.
17. Reece DE, Piza GR, Trudel S, et al. A phase I-II trial of bortezomib (Velcade) (Vc) and oral cyclophosphamide (CY) plus prednisone (P) for relapsed/refractory multiple myeloma (MM). Blood 2005; 106:718a.